Basal serum PRL levels have been reported to be elevated in one-third of patients with PCO (Alger et al., 1980 , Carmina et al., 1984 ., Duignan 1976 , Luciano et al., 1984 . One of the postulated mechanisms which associates elevated PRL with PCO is an abnormal central neurotransmitter, particularly in the dopaminergic control of PRL release (Corenblum and Taylor 1982, Luciano et al., 1984) . Hypothalamic dopamine is known to be the major factor inhibiting PRL secretion. Since LH has also been reported to be suppressed by dopamine (Ferrari et al., 1981 , Leblanc et al., 1976 , Pehrson et al., 1983 , dopamine deficiency may result in hyperprolactinemia and an increase in LH. However, it was demonstrated recently that dopamine can stimulate in vitro release of GnRH from the adult human hypothalamus (Rasmussen et al., 1986) . Further, dopamine antagonist metoclopramide (MCP) was shown to reduce LH in rhesus monkeys (Kaufman et al., 1985) . Since these observations indicate the stimulatory role of dopamine in LH release, they are clearly against the hypothesis that deficient hypothalamic dopamine may play a role in the high prevalence of hyper- (Minakami et al., 1984 (Minakami et al., , 1986 . Intraand interassay coefficients of variation for LH, FSH, and PRL did not exceed 7% and 11%, respectively. Testosterone (T'sterone) and androstenedione (A'dione) levels were determined by radioimmunoassay at Special Reference Lab. (Japan).
Intra-and interassay coefficients of variation for T'sterone were 4.1% and 12.2%, respectively. Those for A'dione were 9.0% and 10.9%, respectively.
Statistical analyses were performed by means of Student's t-test. perprolactinemia cases were transient because the next 5 samples from these 5 women showed normal PRL. The response of PRL to lactotrope stimulating agents MCP and TRH is shown in Fig. 5 . A blunted PRL response after a 10mg intravenous MCP administration was observed in PCO patients when compared to normal women, while the PRL response to TRH in PCO patients was indistinguishable from that in normal women. When compared with the control group examined in the luteal phase, the PRL concentrations after MCP administration in PCO were significantly (p<0.001) low at any time. When compared with the control group examined in the follicullar phase, the PRL values at 30, 60, and 90 minutes after MCP administration in PCO patients were significantly low at p<0.02, p<0.05, and p<0.02, respectively.
Discussion
Earlier, many authors observed the higher incidences of hyperprolactinemia in patients with PCO (Alger et al., 1980 , Carmina et al., 1984 , Duignan 1976 , Luciano et al., 1984 . In the present study, we demonstrated that none of the 72 PCO patients had persistently increased basal PRL. One explanation for this discrepancy may be patient selection. There is an inconsistency in the diagnosis of PCO. Sometimes in clinical and biochemical PCO there is no ovary enlargement (Goldzieher 1981 , Yeh et al., 1987 . On the other hand, multifollicularity of the ovary is sometimes found in anovulatory patients who are apparently different from PCO cases (Adams et al., 1985 , Givens 1984 . Givens (1984) insisted that morphological polycystic ovary was the final expression of several specific entities and thus was a sign and not a specific diagnosis. Therefore the detection of enlarged ovary by palpation or ultrasonography may not be essential to diagnosis as Goldzieher (1981) says. Despite the difference in diagnostic criteria, similarities in the hormonal profile found in our PCO patients with other studies indicate that we are dealing with the same pathology. Even taking into account an inclusion of a heterogenous group of oligo-anovulation in this study, our result shows that none of the patients studied were complicated by persisting hyperprolactinemia which suggests that hyperprolactinemia may be seldom found in PCO. Similar findings were obtained recently by Murdoch et al.,(1986) . It is also of interest to note that MCP caused a more blunted increase in PRL in PCO than in normal woman while the PRL responses to TRH did not differ in PCO and normal women.
Although both PRL and thyrotropin (TSH) are known to be suppressed by dopamine (Morley, 1981) , it has been reported that the PRL response to MCP was decreased while at the same time the TSH response was increased in patients who were considered to have increased central dopamine activity (DeMarinis et al., 1984) . Further, there are several reports which indicate an association between increased dopamine activity and attenuated PRL response to a dopamine receptor blockade (Quigley et al., 1979 , Scanlon et al., 1981 . Recently, Agner et al.,(1986) reported that the infusion of dopamine reduced the PRL response to MCP in normal menstruating women in the follicular phase. The pathophysiological importance of their report is that their experiments may provide evidence of an association between increased dopamine activity and diminished PRL responses to a dopamine receptor blockade. If this is the case, central dopamine activity may be high rather than low in PCO and the reportedly high prevalence of hyperplolactinemia in PCO could not be explained by the deficient central dopamine. In addition, it might be speculated that longstanding increased central dopamine activity may selectively decrease the amount of PRL which should be released in response to dopamine receptor blocking agents.
The concept of a suppressive role of central dopamine in the control of LH release has been supported by the observation that peripherarily administrated dopamine reduced basal LH in normal and hypogonadal women (Ferrari et al., 1981 , Leblanc et al., 1976 , Pehrson et al., 1983 . These effects of dopamine have been believed to act via LHRH suppression because LH response to LHRH was unchanged during dopamine infusion (Pehrson et al., 1983) . The exaggerated decrease in serum LH after dopamine administration observed in PCO by Quigley et al., (1981) further supported the theory of a central dopamine deficiency as a cause of an increase in LH in PCO. However, it was reported by Kaufman et al., (1985) that the dopaminergic blocking agent MCP reduced the frequency of LHRH pulse generator activity, resulting in decreased LH in rhesus monkeys. Kaufman's report (1985) indicates that endogenous dopamine may play a facilitory role in the control of pulsatile LH release. In PCO patients, the frequency of LH pulses is reportedly increased, resulting in an increase in LH (Rebar et al., 1976) . The high frequency of LH pulses found in PCO (Rebar et al., 1976) may result from augmented central dopamine activity. In addition, dopamine was recently reported to stimulate in vitro release of LHRH from the adult human hypothalamus by a dopomine receptor mediated mechanism (Rasmussen et al., 1986) . Since these reports strongly suggest a facilitory role of central dopamine in the LH release by the LHRH mediated mechanism, it is difficult to accept the hypothesis that central dopamine deficiency causes an increase in LH secretion in PCO.
On the basis of our findings and the abovementioned reports, we believe that central dopamine is present and active rather than deficient in PCO patients and therefore the actual incidence of hyperprolactinemia in PCO may be low as observed in this study. The association of hyperprolactinemia with PCO may be a coincidence rather than a pathophysiologically related phenomenon.
